Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy

Epilepsy Research

Volumn 47, Issue 3, 2001, Pages 217-227

  Barton, Matthew E ^a   Klein, Brian D ^a   Wolf, Harold H ^a   White, H Steve ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Animal models; Antiepileptic drugs; Refractory epilepsy; Therapy resistant epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PROTEIN C FOS; TIAGABINE; TOPIRAMATE; TRIMETHADIONE; VALPROIC ACID;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORNEA; DENTATE GYRUS; DRUG EFFICACY; ELECTRIC CURRENT; FOCAL EPILEPSY; GENE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PYRIFORM CORTEX; SEIZURE; STAINING; STIMULATION; STIMULUS RESPONSE; THERAPY RESISTANCE;

ANIMALS; ANTICONVULSANTS; BRAIN; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; EPILEPSIES, PARTIAL; GENES, FOS; GENETIC MARKERS; MALE; MICE; MOTOR ACTIVITY; NEURONS; PSYCHOMOTOR PERFORMANCE; SEIZURES;

EID: 0035652290     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(01)00302-3     Document Type: Article

References (25)

1. Efficacy and safety of UCB L059 as an adjunctive treatment in refractory partial epilepsy: Results of open-label treatment at two centers
2. Properties and alterations of electrically-induced seizures in mice
3. Comparative assay of antiepileptic drugs by 'psychomotor' seizure test and minimal electroshock threshold test
4. Open-label study of UCB L059 as add-on therapy in refractory partial epilepsy
5. Localization and induction of c-fos protein-like immunoreactive material in the nuclei of adult mammalian neurons
6. A note on a simple apparatus for detecting neurological deficit in mice and rats
7. Subacute cannabinoid treatment: Anticonvulsant activity and withdrawal excitability in mice
8. Influence of 22-day treatment on the anticonvulsant properties of cannabinoids
9. Levetiracetam (UCB L059) prevents limbic seizures induced by pilocarpine and kainic acid in rats
10. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
11. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats
12. Antiepileptogenic effects of the novel anticovulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy
13. Validation of corneally kindled mice: A sensitive screening model for partial epilepsy in man
14. Differential spatial patterns of Fos induction following generalized clonic and generalized tonic seizures
15. Regional expression of fos-like immunoreactivity following seizures induced by pentylenetetrazole and maximal electroshock
16. Efficacy and tolerability of UCB L059 add-on treatment in refractory patients with partial-onset epileptic seizures
17. Electrically induced seizures
18. Effects of variations in stimulus intensity on maximal electroshock seizure pattern, recovery time and anticonvulsant potency of phenobarbital in mice
19. Neuropharmacologic considerations in psychic seizures
20. The search for new drugs against epilepsy
21. Anticonvulsant properties of cannabidiol
22. Evaluation of the efficacy and tolerability of UCB L059 in refractory epileptic patients with complex partial seizures: A 12-week, single-blind, add-on, rising-dose study
23. The early identification of anticonvulsant activity: Role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models
24. Discovery and preclinical development of antiepileptic drugs